Zecotek Photonics Inc., a photonics technology company, develops various photonics technologies and products for commercial and research applications in medical, bio-science, high-energy physics, pharmaceutical research, material processing, engineering and industrial design, and multi-media markets. The company operates through three divisions: Zecotek Imaging China, Zecotek Optronics Systems, and Zecotek Autotronics. Its imaging systems include lutetium fine silicate scintillation crystals; solid-state micro-pixel avalanche photo diode photo detectors and transistors; and integrated detector modules. The company also develops glasses-free 3D displays; and 3D auto-stereoscopic displays, and 3D printers and related technologies for applications in healthcare, scientific, and industrial markets. Zecotek Photonics Inc. in Asia and North America. Its strategic partners primarily include Nucare Ltd., University of Washington, and University of California. The company was formerly known as Zecotek Medical Systems Inc. and changed its name to Zecotek Photonics Inc. in November 2007. Zecotek Photonics Inc. was incorporated in 1983 and is headquartered in Richmond, Canada.
Industry, Sector and Symbol
Industry Medical Appliances & Equipment
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone+1-604-2330056
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesC$13,015.00
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date4/1/2019 (Estimated)
OptionableNot Optionable
Zecotek Photonics (CVE:ZMS) Frequently Asked Questions
What is Zecotek Photonics' stock symbol?
Zecotek Photonics trades on the Canadian Venture Exchange (CVE) under the ticker symbol "ZMS."
When is Zecotek Photonics' next earnings date?
Has Zecotek Photonics been receiving favorable news coverage?
Media headlines about ZMS stock have been trending somewhat negative recently, InfoTrie Sentiment reports. InfoTrie rates the sentiment of media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Zecotek Photonics earned a news impact score of -1.5 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the next few days.
Who are some of Zecotek Photonics' key competitors?
What other stocks do shareholders of Zecotek Photonics own?
Who are Zecotek Photonics' key executives?
Zecotek Photonics' management team includes the folowing people:
- Dr. A. Faouzi Zerrouk, Founder, Chairman, Chairman of Scientific Advisory Board, CEO & Pres
- Mr. Azman Ariffin, Chief Operations Officer
- Dr. Serge Khorev, Sr. VP of Technology
- Prof. Zair Sadygov, Chief Scientist of Medical Imaging Division
- Ms. Shirley Kancs, Assistant Sec. (Age 66)
How do I buy shares of Zecotek Photonics?
Shares of ZMS and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is Zecotek Photonics' stock price today?
One share of ZMS stock can currently be purchased for approximately C$0.04.
How big of a company is Zecotek Photonics?
Zecotek Photonics has a market capitalization of C$6.60 million and generates C$13,015.00 in revenue each year.
What is Zecotek Photonics' official website?
How can I contact Zecotek Photonics?
Zecotek Photonics' mailing address is Unit 1120 - 21331 Gordon Way, RICHMOND, BC V6W 1J9, Canada. The company can be reached via phone at +1-604-2330056.
MarketBeat Community Rating for Zecotek Photonics (CVE ZMS)
MarketBeat's community ratings are surveys of what our community members think about Zecotek Photonics and other stocks. Vote "Outperform" if you believe ZMS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZMS will underperform the S&P 500 over the long term. You may vote once every thirty days.
